-
Mashup Score: 1Aldosterone in chronic kidney disease and renal outcomes - 2 year(s) ago
AbstractAims. Randomized controlled trials have demonstrated the efficacy of mineralocorticoid receptor (MR) antagonism in delaying chronic kidney disease (CKD)
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2Diabetic Kidney Disease 2022 Update - 2 year(s) ago
Presentation given to our fellowship program about diabetic kidney disease. 2022 update discussing SGLT2i, MRA (e.g. finerenone), health economics and beyond
Source: www.slideshare.netCategories: Cardiologists, Latest HeadlinesTweet-
RT @ChristosArgyrop: Diabetic Kidney Disease 2022 Update by @ChristosArgyrop https://t.co/UCE7XGodfN via @SlideShare #flozination #MRA #fi…
-
-
Mashup Score: 2Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction - 2 year(s) ago
Background: The TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) suggested clinical benefits of spironolactone treatment among patients with h
Source: Circulation: Heart FailureCategories: Cardiologists, Latest HeadlinesTweet-
#Spironolactone therapy was associated with proteome-wide significant changes in 7 proteins This study suggest potential #antiapoptotic effects of spironolactone in #HFpEF , a hypothesis that merits further exploration @CircAHA #HeartFailure #MRA https://t.co/HaYlE9Bvxi
-
-
Mashup Score: 1
Abstract. Despite existing treatments, patients with heart failure and chronic kidney disease (CKD) remain at high risk for adverse outcomes and progression to
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Discover more in EHJ! https://t.co/uXgDv0tB61 #MRA #cardiorenal #HF #CKD #cardiotwitter @escardio @ESC_Journals https://t.co/hLuUrxNja2
-
-
Mashup Score: 0Potassium Binders for Patients With Heart Failure? The Real Enlightenment of the DIAMOND Trial - 2 year(s) ago
Milton Packer, M.D; Potassium Binders for Patients With Heart Failure? The Real Enlightenment of the DIAMOND Trial, European Heart Journal, , ehac399, https://d
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Potassium Binders for Patients With Heart Failure? The Real Enlightenment of the DIAMOND Trial! https://t.co/9eoJwdqiB5 #HFrEF #MRA #patiromer #cardiotwitter @escardio @ESC_Journals https://t.co/teEQgQqo2j
-
-
Mashup Score: 0
Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease – Full Text View.
Source: clinicaltrials.govCategories: Cardiologists, Latest HeadlinesTweet-
@bmorecardiology @MKIttlesonMD @HFSA @CardioNerds @gcfmd @ATRIUMRx An example of combo being tested is P2 #MIRACLE RCT in HF+CKD: #SGLT2i alone vs. Combo #SGLT2i + 3 doses of partial #MRA (w ↓ hyperK risk) While we typically don't consider a dose relationship w MRA, one likely exists w ↑ doses only limited by hyperK https://t.co/qAFBZgNDK4
-
-
Mashup Score: 4Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction: - 2 year(s) ago
Abstract Background Mineralocorticoid receptor antagonists (MRAs) may be beneficial in reducing heart failure (HF) hospitalizations in patients with HF with preserved ejection fraction. The effect …
Categories: Cardiologists, Latest HeadlinesTweet-
In patients with #HFpEF, treatment with #empagliflozin improves clinical outcomes regardless of background #MRA therapy https://t.co/KvfwuvXkCV @JACCJournals #JACC @unic_cardiovasc @JavedButler1 @FaiezZANNAD #MiltonPacker @robmentz @BiykemB @HFpEF @ShelleyZieroth https://t.co/HqkZZQwq5T
-
https://t.co/O0xQZ8Qc6k
-
📁https://t.co/xJaoR1sfrf
-
-
Mashup Score: 0Empagliflozin beneficial in HF with reduced ejection fraction, despite other therapies - 2 year(s) ago
Adults with heart failure with reduced ejection fraction derived similar benefits with empagliflozin regardless of other disease-modifying heart failure therapies prescribed at baseline, post hoc analysis of the EMPEROR-Reduced trial show. “The EMPEROR-Reduced trial required patients to be treated for heart failure, but did not mandate specific doses or specific drugs,” Subodh Verma,
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
In #HFrEF, the SGLT2 inhibitor #empagliflozin reduced risk for the primary outcome in EMPEROR-Reduced irrespective of background treatments, including triple therapy with an ACE inhibitor, ARB, or ARNI, beta-blocker plus an #MRA. @CardiologyToday https://t.co/VZU3uUlx7u
-
In #HFrEF, the SGLT2 inhibitor #empagliflozin reduced risk for the primary outcome in EMPEROR-Reduced irrespective of background treatments, including triple therapy with an ACE inhibitor, ARB, or ARNI, beta-blocker plus an #MRA. @CardiologyToday https://t.co/XwFsYQndPn
-
-
Mashup Score: 23Re-emergence of heart failure with a normal ejection fraction? - 2 year(s) ago
This editorial refers to ‘Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction’, by J. Butler et al.
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Re-emergence of HF with a normal EF? in #EHJ by #Kondo & #McMurray. Do treatment effects of #SGLT2i attenuate at higher #LVEF similar to #ARB #ARNI #MRA & #digitalis? Stay tuned for #DELIVER in '22 evaluating dapa in 6,263 pts, incl 1,892 with LVEF≥60%. https://t.co/iiiYIECbrL https://t.co/3UrKrBXzto
-
-
Mashup Score: 3
Purpose The activation of the renin-angiotensin-aldosterone system prevents the uptake of norepinephrine and promotes structural remodeling of the heart. The mineralocorticoid receptor antagonist (MRA) eplerenone prevents left ventricular (LV) remodeling in patients with acute myocardial infarction, but its influence on cardiac sympathetic nerve activity (CSNA) has not been determined. Methods We…
Source: link.springer.comCategories: Cardiologists, Latest HeadlinesTweet-
Effects of #MRA eplerenone on cardiac sympathetic nerve activity and left ventricular remodeling after reperfusion therapy in patients with first #STEMI #Eplerenone improves CSNA and prevents LV remodeling in patients with a first STEMI https://t.co/y4CZ24ebIp @JNCjournal https://t.co/MrpBUA8cSB
-
#Aldosterone in CKD and renal outcomes These observational data suggest that pathogenic #aldosteronism may play a role in CKD progression #MRA therapy as a method to delay CKD progression in those without #DM ? https://t.co/eQsr7Np7Gn #EHJ #HeartFailure @ESC_Journals https://t.co/KW4FjhyLpC